Montreal General Hospital

Celltrion Healthcare announces the addition of a Yuflyma® (adalimumab) 80 mg dosing option, available as an auto-injector and pre-filled syringe

Retrieved on: 
Wednesday, August 30, 2023
McGill University Health Centre, Injection, QC, Adalimumab, Department of Medicine – University of Pamplona, Pharmacy, Montreal General Hospital, CGMP, MD, Patient, McGill University, Growth, Commercial, Health Canada, Celltrion, Pharmaceutical industry, Health insurance

Celltrion Healthcare Canada Limited remains committed to providing a patient centric approach, to ensure access to innovative, high-quality biologics in Canada

Key Points: 
  • Celltrion Healthcare Canada Limited remains committed to providing a patient centric approach, to ensure access to innovative, high-quality biologics in Canada
    TORONTO, Aug. 30, 2023 /CNW/ - Celltrion Healthcare Canada Limited today announced that Yuflyma® (adalimumab) is now available in an 80 mg auto-injector and pre-filled syringe.
  • "We are proud to give patients the choice of fewer injections, in their device of choice – an auto-injector or pre-filled syringe."
  • In addition to the availability of Yuflyma® 80 mg, Celltrion Healthcare Canada is also proud to offer CELLTRION CONNECT™, a patient-focused support program tailored to support patients and healthcare providers.
  • Yuflyma® is manufactured by Celltrion Healthcare Co., Ltd. and distributed by Celltrion Healthcare Canada Limited.

Rio Tinto donates $500,000 to the MUHC Foundation to fight antimicrobial resistance

Retrieved on: 
Tuesday, November 22, 2022
McGill University Health Centre, COVID-19, Research institute, McGill, Rio, Hospital, Rio Tinto, Risk, Montreal General Hospital, Life, Bacteria, Hepatitis C, Health, Patient, Faculty, Disinfectant, Medical school, Glen, Krembil Research Institute, Medicine, Transplant, Education, AMR, MUHC, Tuberculosis, Fonds, McGill University, Research, MI4, Iron ore, Antibiotics, Vaccine, Pharmaceutical industry, Infection, Immunity

Thanks to a $500,000 gift from Rio Tinto to the McGill Antimicrobial Resistance Centre, made through the Rio Tinto Aluminium Canada Fund, new innovations in the fight against resistant bacteria will be developed in Montreal.

Key Points: 
  • Thanks to a $500,000 gift from Rio Tinto to the McGill Antimicrobial Resistance Centre, made through the Rio Tinto Aluminium Canada Fund, new innovations in the fight against resistant bacteria will be developed in Montreal.
  • To help scientists at the Research Institute of the McGill University Health Centre and McGill University find innovative ways to curb infection, Rio Tintos gift will create the Antimicrobial Resistance Discovery Incubator.
  • Antimicrobial resistance is a global issue and, as a global company, Rio Tinto is pleased to support research that will have a positive impact on peoples health worldwide.
  • The impact of Rio Tintos gift to the new Antimicrobial Resistance Discovery Incubator has the potential to reverberate around the globe.

McGill Antimicrobial Resistance Centre to tackle one of humanity’s greatest threats

Retrieved on: 
Monday, September 19, 2022
Medical school, Health, Power Corporation of Canada, McGill, Education, COVID-19, Transplant, Hepatitis C, Risk, MI4, Hospital, McGill University Health Centre, Corporation, Faculty, Disinfectant, Kenya Medical Research Institute, Fonds, Life, AMR, Partnership, Patient, MUHC, Public health, Solution, Bacteria, Humanity, McGill University, Glen, Research, GLOBE, Medicine, Research institute, Montreal General Hospital, Antibiotics, Pharmaceutical industry, Vaccine, Infection, Immunity

MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Antimicrobial resistance (AMR) is a global scale threat to human life and economic prosperity.

Key Points: 
  • MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Antimicrobial resistance (AMR) is a global scale threat to human life and economic prosperity.
  • With the launch of the new McGill Antimicrobial Resistance (AMR) Centre, a partnership between McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC), Montreal is becoming a powerhouse in understanding and preventing AMR.
  • The McGill University Health Centre (MUHC) Foundation raises funds to support excellence in patient care, research and teaching at the McGill University Health Centre, one of the top university hospitals in Canada.
  • www.muhcfoundation.com
    The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre.

CIBC donates $1M to support the future of patient-centered care at the MUHC

Retrieved on: 
Tuesday, June 14, 2022
MUHC, Vital signs, Ministry of Economy and Innovation (Lithuania), Radiation therapy, Gaps, McGill University Health Centre, Technology, Research, Gibbs Cancer Center & Research Institute, Medicine, Inflammatory bowel disease, Glen, Cancer, CHU, Research institute, Team, Faculty, Smartcar (company), Health, Parent, HIV, Patient, Computer science, Medical school, Montreal General Hospital, Roche, Opal, Innovation, CIBC, Physician, Ministry, Â, McGill University, Infection, Kidney disease, Education, Public sector, Breast cancer, News, Investment, Intelligence, Student, GLOBE, Anomaly, Novartis, Hospital, Fonds, Pharmaceutical industry, Medical imaging

An innovative app improving the patient experience at the MUHC is expanding thanks to a $1 million gift from CIBC to the MUHC Foundation.

Key Points: 
  • An innovative app improving the patient experience at the MUHC is expanding thanks to a $1 million gift from CIBC to the MUHC Foundation.
  • It will also provide patients the reassurance that anomalies in their health will be noticed by their health care team and addressed quickly.
  • Patients will be able to share their anonymized data with scientists to enable studies that will ultimately improve patient care.
  • The MUHC Foundation is grateful to CIBC for its generous gift to support Opal.

Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis

Retrieved on: 
Tuesday, May 31, 2022
Department, Physician, UC, Metabolism, Doctor of Philosophy, Private Securities Litigation Reform Act, Hospital, Journal, University of Oxford, DDW, Nasdaq, Ulcerative colitis, Endoscopy, Proteomics, Patient, Financial condition report, Result, Analysis, UZ Leuven, Therapy, National university, Serri, Sardinia, COVID-19, Genetics, Trial of the century, Research, IBD, McGill University, Gastroenterology, SAN, Industry, Prijs der Nederlandse Letteren, Montreal, University, KU Leuven, Safety, Montreal General Hospital, Gastrointestinal disease, Precision medicine, SEC, GI, MD, Wellcome Trust Centre for Gene Regulation and Expression, Annual report, GLOBE, Medical device, Medical imaging, Pharmaceutical industry, Medicine, Colitis

In the presentation, Dr. Vermiere presented patient data confirming a significant relationship between drug levels in tissue and endoscopic improvement in patients with moderate to severe ulcerative colitis (UC) who were treated with tofacitinib.

Key Points: 
  • In the presentation, Dr. Vermiere presented patient data confirming a significant relationship between drug levels in tissue and endoscopic improvement in patients with moderate to severe ulcerative colitis (UC) who were treated with tofacitinib.
  • This study supports the hypothesis that a tissue concentration of tofacitinib at or exceeding IC90 is directly correlated to significant improvement in patient outcomes, Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
  • Our targeted delivery platform is uniquely positioned to be able to safely deliver the desired amount of drug to the diseased tissue in UC.
  • We recently also shared data about the potential importance of combination therapy for the UC patient community.

Two-Thirds of Canadian Gen Z Homebuyers Say Personal Savings Will Be a Primary Source of Down Payment Funds

Retrieved on: 
Wednesday, March 9, 2022
Housing, Greater Toronto Area, TFSA, Family, Friends, CMA, General manager, Statistics, Canada, CMAS, Retirement, Generation, Health, Child, Generation Z, GLOBE, Sale, Statistics Canada, Ownership, Gen, Overalls, Probability, HPI, CEO, Montreal General Hospital, Travel, Online gambling, Health insurance, Bank, Tutoring, Renewable energy, Real estate, Oil, Video game

TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- A new generational trends report released today by Mustel Group and Sotheby’s International Realty Canada reveals that even in light of escalating costs of living and rising housing prices nationwide, an overwhelming majority of Generation Z buyers are self-reliant in saving for their first homes, and are employing diverse strategies to overcome financial obstacles to home ownership.

Key Points: 
  • 67% report that personal savings will be a primary source of funds for their down payment.
  • Newly released findings reveal that the most common source of funds for their down payments will be personal savings, with 67% of urban Canadian Generation Z adults reporting this as a primary source.
  • An overwhelming 70% of survey respondents say personal savings will be a primary funding source for their down payment.
  • 64% of respondents indicate that personal savings will be a primary funding source for their down payment.

BMO donates $2M to the MUHC Foundation for precision cancer care

Retrieved on: 
Friday, December 10, 2021
Life, Patient, Student, McGill University Health Centre, Health, Faculty, Commercial bank, BMO Capital Markets, Education, BMO, Hospital, Organoid, Program, Fonds, Organization, Bank of Montreal, Cancer, Research, MUHC, Gibbs Cancer Center & Research Institute, McGill University, Glen, Medicine, Medical school, Precision, Montreal General Hospital, Quality of life, Infection, Adult, Research institute, Oncology, Survival, GLOBE, Pharmaceutical industry, Medical imaging

Precision oncology is the future of cancer care.

Key Points: 
  • Precision oncology is the future of cancer care.
  • We are incredibly grateful to BMO for supporting the development of the Precision Oncology Program at the Research Institute of the MUHC.
  • The gift is part of the MUHC Foundations $20 million campaign to End Cancer as a deadly disease.
  • The MUHC thanks BMO Financial Group for its leadership gift and appeals to other organizations to help us develop the next generation of precision medicines against cancer.

Promising COVID-19 Therapeutic Drug to start Phase 3 Clinical Trial in the United States

Retrieved on: 
Monday, November 22, 2021
Patient, Fonds, Dapsone, CEO, Pneumocystis pneumonia, MUHC, McGill University, Safety, Kenya Medical Research Institute, Research institute, Hospital, Health, McGill University Health Centre, Health Canada, Inflammation, Solution, Faculty, Therapy, Institute, Lupus, COVID-19, Research, Montreal General Hospital, GLOBE, Medical school, Malaria, Tablet, Epidemiology, FDA, Mortality, Innovative Medicines Initiative, Infection, Glen, Acute respiratory distress syndrome, Nasal spray, HIV, Pharmaceutical industry

The drug was previously used to treat infectious diseases, including malaria, lupus, Human Immunodeficiency Virus (HIV) and pneumocystis pneumonia.

Key Points: 
  • The drug was previously used to treat infectious diseases, including malaria, lupus, Human Immunodeficiency Virus (HIV) and pneumocystis pneumonia.
  • Upon successful completion of the Phase 3 Clinical Trial, PULM-001 could be procured by governments and distributed through existing, well-established government networks.
  • The Phase 3 Clinical Trial will take place in North Carolina, Washington and Idaho under the sponsorship of Peters Medical Research and Principal Research Solutions.
  • Pulmonem anticipates a US$6 to $8 million financing will be required by early 2022 to complete the Phase 3 Clinical Trial.

Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702

Retrieved on: 
Monday, November 15, 2021
Quality of life, Safety, University, McGill University, Glucocorticoid, Associate, Health, Montreal General Hospital, Eastern Time Zone, Ann Arbor, Michigan, Knowledge, University of Michigan, Swelling, Technology, Inflammation, KOL, Epidemiology, Rheumatoid arthritis, Nonsteroidal anti-inflammatory drug, Scleroderma, Research, McGill, Colchicine, ACR, Internal medicine, Gaps, American College, American College of Rheumatology, Pain, GLOBE, Lewis Dyve, Metabolism, University of California, San Diego Performance-Based Skills Assessment, NCE, Q&A, Michigan Medicine, Gout, UC San Diego School of Medicine, Public health, Patent, Patient, NIH, ULT, EULAR, Medical device, Pharmaceutical industry

Webinar to be held Tuesday, November 23rd @ 11am ET

Key Points: 
  • Webinar to be held Tuesday, November 23rd @ 11am ET
    THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (Dyve), a clinical stage biotechnology company,today announced that it will host a key opinion leader (KOL) webinar on gout on Tuesday, November 23, 2021 at 11:00am Eastern Time.
  • Both experts will discuss the current treatment landscape for gout and unmet medical need in treating the pain, swelling, and discomfort associated with gout flares.
  • DYV702 demonstrated a statistically significant improvement in overall response rate, lower rescue medication use, and an improvement in physical function.
  • Dyves lead asset, DYV702,recently completed a 20-center, 100-patient, Phase 2 clinical study for the treatment ofpainassociated with acute gout.